918 related articles for article (PubMed ID: 20463596)
21. Novel peptide-based vaccines efficiently prime murine "help"-independent CD8+ T cell responses in the liver.
Dikopoulos N; Riedl P; Schirmbeck R; Reimann J
Hepatology; 2004 Aug; 40(2):300-9. PubMed ID: 15368434
[TBL] [Abstract][Full Text] [Related]
22. Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines.
Dobaño C; Rogers WO; Gowda K; Doolan DL
Immunol Lett; 2007 Aug; 111(2):92-102. PubMed ID: 17604849
[TBL] [Abstract][Full Text] [Related]
23. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
24. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
[TBL] [Abstract][Full Text] [Related]
25. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
[TBL] [Abstract][Full Text] [Related]
26. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
27. Inverted terminal repeat sequences of adeno-associated virus enhance the antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera.
Chikhlikar P; Barros de Arruda L; Agrawal S; Byrne B; Guggino W; August JT; Marques ET
Virology; 2004 Jun; 323(2):220-32. PubMed ID: 15193918
[TBL] [Abstract][Full Text] [Related]
28. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.
Wu A; Zeng Q; Kang TH; Peng S; Roosinovich E; Pai SI; Hung CF
Gene Ther; 2011 Mar; 18(3):304-12. PubMed ID: 20981112
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments.
Cheng WF; Hung CF; Hsu KF; Chai CY; He L; Ling M; Slater LA; Roden RB; Wu TC
Hum Gene Ther; 2001 Feb; 12(3):235-52. PubMed ID: 11177561
[TBL] [Abstract][Full Text] [Related]
30. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
31. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
[TBL] [Abstract][Full Text] [Related]
32. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death.
Kim TW; Hung CF; Juang J; He L; Hardwick JM; Wu TC
Gene Ther; 2004 Feb; 11(3):336-42. PubMed ID: 14737094
[TBL] [Abstract][Full Text] [Related]
34. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity.
Kim JH; Chen J; Majumder N; Lin H; Falo LD; You Z
Gene Ther; 2005 Oct; 12(20):1517-25. PubMed ID: 16052205
[TBL] [Abstract][Full Text] [Related]
35. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity.
Lin CT; Chang TC; Shaw SW; Cheng PJ; Huang CT; Chao A; Soong YK; Lai CH
Vaccine; 2006 Sep; 24(37-39):6199-207. PubMed ID: 16824651
[TBL] [Abstract][Full Text] [Related]
36. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
37. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cell.
Kim D; Hoory T; Wu TC; Hung CF
Hum Gene Ther; 2007 Nov; 18(11):1129-39. PubMed ID: 17939748
[TBL] [Abstract][Full Text] [Related]
38. A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response.
Kim TW; Hung CF; Zheng M; Boyd DA; He L; Pai SI; Wu TC
J Biomed Sci; 2004; 11(4):493-9. PubMed ID: 15153784
[TBL] [Abstract][Full Text] [Related]
39. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
40. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells.
Radcliffe JN; Roddick JS; Friedmann PS; Stevenson FK; Thirdborough SM
J Immunol; 2006 Nov; 177(10):6626-33. PubMed ID: 17082574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
